Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Jul 26, 2011	EDAP Schedules Webcast and Conference Call of Second Quarter 2011 Results LYON, France , July 26, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its second quarter 2011 results announcement, which will take place on Tuesday, August 30, 2011 , before the opening of the market.	View HTML EDAP Schedules Webcast and Conference Call of Second Quarter 2011 Results 14.6 KB
Toggle Summary Jun 14, 2011	EDAP Secures Market Clearance for Its Sonolith(R) Lithotripters in Major Asian Markets -- Latest and Modular Model, Sonolith® i-move, is Now Approved in Japan -- -- Fully Integrated and Robotized Model, Sonolith® i-sys, is Approved in Taiwan -- LYON, France , June 14, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the	View HTML EDAP Secures Market Clearance for Its Sonolith(R) Lithotripters in Major Asian Markets 15 KB
Toggle Summary May 25, 2011	EDAP to Showcase Ablatherm(R) HIFU Data at 4th International Symposium on Focal Therapy & Imaging in Prostate & Kidney Cancer LYON, France , May 25, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced two abstracts supporting the Ablatherm ® High Intensity Focused Ultrasound's (HIFU) efficacy for the treatment of localized prostate cancer will be featured at the	View HTML EDAP to Showcase Ablatherm(R) HIFU Data at 4th International Symposium on Focal Therapy & Imaging in Prostate & Kidney Cancer 15 KB
Toggle Summary May 24, 2011	EDAP Reports First Quarter 2011 Financial Results First Quarter 2011 Highlights Lithotripsy division revenues increased 28.9% year-over-year to EUR 3.5 million ( USD 4.9 million ), fueled by innovative product line Gross profit increased 15.2% to EUR 2.0 million ( USD 2.7 million ) Total operating expenses declined 14.6% year-over-year to EUR 2.6	View HTML EDAP Reports First Quarter 2011 Financial Results 28.8 KB
Toggle Summary May 17, 2011	Largest Long-Term Study Confirms EDAP's Ablatherm® HIFU is Effective, Highly Reproducible Primary Treatment for Localized Prostate Cancer -- 2,552 Patient, International, Multi-Center, 10-year Study Shows 83% of Patients Cancer Free --	View HTML Largest Long-Term Study Confirms EDAP's Ablatherm® HIFU is Effective, Highly Reproducible Primary Treatment for Localized Prostate Cancer 16.1 KB
Toggle Summary May 12, 2011	EDAP Features New Ablatherm(R) HIFU Data Supporting Superior Efficacy for Treatment of Local Prostate Cancer at American Urological Association Annual Meeting LYON, France , May 12, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced Ablatherm ® High Intensity Focused Ultrasound (HIFU) will be featured in four presentations supporting the technology's efficacy for the treatment of localized	View HTML EDAP Features New Ablatherm(R) HIFU Data Supporting Superior Efficacy for Treatment of Local Prostate Cancer at American Urological Association Annual Meeting 15.7 KB
Toggle Summary May 10, 2011	EDAP Schedules Webcast and Conference Call of First Quarter 2011 Results LYON, France , May 10, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its first quarter 2011 results announcement, which will take place on Tuesday, May 24, 2011 , before the opening of the market.	View HTML EDAP Schedules Webcast and Conference Call of First Quarter 2011 Results 14.6 KB
Toggle Summary May 09, 2011	Published 15-Year Clinical Review Supports EDAP's Ablatherm(R) HIFU as Viable Primary Treatment for Local Prostate Cancer at Any Stage Study to Appear in June 2011 Current Urology Report	View HTML Published 15-Year Clinical Review Supports EDAP's Ablatherm(R) HIFU as Viable Primary Treatment for Local Prostate Cancer at Any Stage 17.9 KB
Toggle Summary Apr 20, 2011	EDAP Highlights Innovative Sonolith i-move Lithotripter at the Annual Japanese Urological Association Meeting EDAP Pursues Lithotripsy Expansion Strategy	View HTML EDAP Highlights Innovative Sonolith i-move Lithotripter at the Annual Japanese Urological Association Meeting 15.1 KB
Toggle Summary Apr 14, 2011	EDAP and Collaboration Partners Awarded EUR 1.1 Million European Grant for HIFU Triggered Drug Delivery Program Technology Focuses on Facilitating Ultrasound Assisted Drug Delivery	View HTML EDAP and Collaboration Partners Awarded EUR 1.1 Million European Grant for HIFU Triggered Drug Delivery Program 17.9 KB